Sampley Supriya, Bhasin Deepak, Sekhri Kavita, Singh Harpal, Gupta Onkar
Medical Intensive Care Unit, Max Super Speciality Hospital, Mohali, Punjab, India.
Department of Pulmonology and Critical Care, Max Super Speciality Hospital, Mohali, Punjab, India.
Indian J Crit Care Med. 2024 Jan;28(1):70-74. doi: 10.5005/jp-journals-10071-24594.
Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in covid. We share our experience with this molecule by doing a retrospective study to evaluate the effect of this drug on clinical outcomes in viral-related Ards patients.
In this study, all patients with severe viral-related Ards received Aviptadil along with the conventional treatment. The oxygen saturation, SpO/FiO (ratio of pulse oximetric saturation to fractional inspired oxygen) (S/F) ratio and PaO/FiO (ratio of arterial oxygen partial pressure to fractional inspired oxygen) (p/f) ratio, before and after completion of the drug were studied. Radiological clearance and time for complete recovery from respiratory failure was noted. All variables pre- and postadministration of the drug were compared.
A total of 68 patients with viral pneumonias were admitted to intensive care unit (Icu) and only 6 patients had severe Ards, who received Aviptadil. The mean oxygen saturation significantly improved from 87.86% before the first Aviptadil dose to 93.43% post 3 days of infusion. Similarly, improvement was seen in PaO values from 54.32 to 68.4 posttherapy (-value < 0.004). SpO/FiO (ratio of pulse oximetric saturation to fractional inspired oxygen) ratio hiked from 149 to 336 at the end of the 3 days infusion (-value < 0.003). RALE scoring system was used for radiological clearance and the mean change in the score was from 6.42 to 2.5 (-value 0.00). The average length of stay in the Icu was 12.14 days. No adverse effects were noted.
Aviptadil has shown to improve the clinical outcomes in patients with severe viral-related ards without any adverse effects.
Sampley S, Bhasin D, Sekhri K, Singh H, Gupta O. Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS: A Retrospective Observational Study. Indian J Crit Care Med 2024;28(1):70-74.
应对危及生命的病毒性急性呼吸窘迫综合征（ARDS）一直具有挑战性，且鉴于近期新冠疫情的经验，仍需要更新的疗法来降低死亡率。阿维普他定在新冠治疗中已显示出显著的有益效果。我们通过一项回顾性研究分享我们对该药物的经验，以评估其对病毒性ARDS患者临床结局的影响。
在本研究中，所有重症病毒性ARDS患者在接受常规治疗的同时接受阿维普他定治疗。研究了用药前后的血氧饱和度、SpO₂/FiO₂（脉搏血氧饱和度与吸入氧分数之比）（S/F）比值以及PaO₂/FiO₂（动脉血氧分压与吸入氧分数之比）（p/f）比值。记录了影像学清除情况以及从呼吸衰竭完全恢复的时间。比较了用药前后的所有变量。
共有68例病毒性肺炎患者入住重症监护病房（ICU），只有6例重症ARDS患者接受了阿维普他定治疗。首次使用阿维普他定前的平均血氧饱和度为87.86%，输注3天后显著提高至93.43%。同样，治疗后PaO₂值从54.32提高到68.4（p值<0.004）。输注3天结束时，SpO₂/FiO₂比值从149提高到336（p值<0.003）。采用啰音评分系统评估影像学清除情况，评分的平均变化从6.42降至2.5（p值0.00）。在ICU的平均住院时间为12.14天。未观察到不良反应。
阿维普他定已显示可改善重症病毒性ARDS患者的临床结局，且无任何不良反应。
Sampley S, Bhasin D, Sekhri K, Singh H, Gupta O. 新型疗法阿维普他定对病毒性重症ARDS患者临床结局的影响：一项回顾性观察研究。《印度危重症医学杂志》2024；28(1):70 - 74。
